Telix Pharmaceuticals 1H25 NPAT up 860% to $49.9m, FY25 revenue guidance of $1.18-1.23bn vs. $1.02bn consensus, R&D ...
The Daily: JPMorgan warns of crypto downside risk, Hashdex set to launch world's first spot XRP ETF and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback